MRK vs BIIB
By Alex · Tickerpine
Merck & Co., Inc. vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BIIB |
|---|---|---|
| Price | $147.76 | $253.40 |
| Market cap | $364.26B | $37.46B |
| P/E ratio | 149.3 | 109.7 |
| ROE | 5.06% | 1.87% |
| Profit margin | 3.64% | 3.38% |
| Revenue growth | 4.70% | 10.60% |
| Dividend yield | 2.30% | 0.00% |
| Beta | 0.12 | 0.09 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BIIB in plain English
- MRK is the bigger company — about 9.7× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 109.7 vs 149.3).
- MRK earns a higher return on equity (5% vs 2%).
- BIIB is growing revenue faster (11% vs 5%).
- MRK pays a dividend (2.30%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.